Status:
UNKNOWN
Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) Recurrence
Lead Sponsor:
Taipei Veterans General Hospital, Taiwan
Conditions:
HCC Patients After Curative Treatment With Low HBV Viral Load
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
Hepatocellular carcinoma(HCC) is prevalent in the hepatitis B virus(HBV) infection endemic areas. For early stage of HCC, surgical resection, radiofrequency ablation (RFA) or microwave ablation (MWA) ...
Eligibility Criteria
Inclusion
- HBsAg-positive for more than 6 months.
- HCC after curative treatment (eight by surgical resection or RFA or MWA) with significant liver fibrosis (either by Ishak≧2, Metavir≧2, Knodell≧3) or cirrhosis and HBV DNA\<2,000 IU/ml.
- The duration of curative treatment of HCC to study enrollment should be less than 90 days.
- Curative treatment is confirmed by contrast-enhanced CT or MR after the surgery/RFA/MWA.
Exclusion
- Child-Pugh class B8-C.
- Active EV bleeding within 4 weeks.
- History of hepatic encephalopathy or intractable ascites.
- BCLC C or D.
Key Trial Info
Start Date :
October 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
402 Patients enrolled
Trial Details
Trial ID
NCT04290936
Start Date
October 16 2020
End Date
December 31 2024
Last Update
July 9 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, State..., Taiwan, 807
2
National Taiwan University Hospital
Taipei, State..., Taiwan, 100
3
Tri-Service General Hospital
Taipei, State..., Taiwan, 114
4
Taipei Veterans General Hospital
Taipei, Taiwan, 11217